DIVERGIMAB
Live / Registered — Registered (as of 05 Mar 2024)
What this means for you
Registered since 05 Mar 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90826231
- Registration number
- 7323273
- Mark type
- Stylized text
- Filed
- 13 Jul 2021
- Published for opposition
- 19 Jul 2022
- Registered
- 05 Mar 2024
- Attorney of record
- Mark Leonardo
Goods and services
- Class 042 — Scientific and technological services: Scientific research services for others in the field of genetics and monoclonal antibodies; Research and development services in the field of monoclonal antibodies, namely, development of antibody-based therapeutics and discovery of reagents; Research and development services in the field of monoclonal antibodies, namely, generation of therapeutic and reagent antibodies; Genetic engineering services, namely, the production of genetically-engineered mice and monoclonal antibodies for others
Owner
- AbX Biologics, Inc., Canton, MA, US
- AbX Biologics, Inc., Canton, MA, US
- AbX Biologics, Inc., Canton, MA, US
Prosecution history
- 05 Mar 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 05 Mar 2024 — REGISTERED-PRINCIPAL REGISTER
- 30 Jan 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 30 Jan 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 30 Jan 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 30 Jan 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 29 Jan 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 15 Sept 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 15 Sept 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 15 Sept 2023 — ASSIGNED TO LIE
- 01 May 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 22 Mar 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 22 Mar 2023 — NON-FINAL ACTION E-MAILED
- 22 Mar 2023 — SU - NON-FINAL ACTION - WRITTEN
- 08 Mar 2023 — STATEMENT OF USE PROCESSING COMPLETE